Medicxi Funds Complete Sale of Centessa Pharmaceuticals Shares in Eli Lilly Acquisition

This Form 4 filing reports that multiple Medicxi investment funds have disposed of their entire holdings in Centessa Pharmaceuticals plc (CNTA) as part of Eli Lilly and Company's acquisition of the company. On June 24, 2026, Eli Lilly, through its subsidiary LDH XV Corporation, acquired all outstanding Ordinary Shares of Centessa via a UK scheme of arrangement. The Medicxi funds, including Medicxi Ventures I LP, Medicxi Growth I LP, Medicxi Secondary I LP, and their co-investment vehicles, sold a total of approximately 20 million shares. Shareholders received $38.00 in cash per share plus one contingent value right (CVR) worth up to $9.00 per share, contingent on achieving specified milestones. The transaction was automatic at the effective time of the scheme of arrangement, and all reporting persons now hold zero shares in the company.